Autopsy lung section from a fatal case of H1N1 influenza shows severe acute and organizing lung injury, a nonspecific pattern requiring clinical, laboratory, or IHC correlation for definitive diagnosis.

Chest radiograph of a 61-year-old man with chronic lymphocytic leukemia and an acute influenza infection shows bilateral asymmetric patchy airspace and interstitial opacities.(From DI2: Chest.)
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Influenza Virus {#cesec2}
---------------

### Terminology {#cesec3}

•Synonyms: "The flu"

### Etiology/Pathogenesis {#cesec4}

•Viral infections transmitted person to person via respiratory droplets•Incubation period: 1-4 days•Infectious period: 1 day before until 5 days after onset of symptoms•Hemagglutinin (HA) binds sialic acids on cell surface causing viral uptake into host cells•Neuraminidase (NA) enzymatically removes sialic acids, promoting viral release from infected cells•Antigenic drift: Production of new viral strains by mutations in HA and NA genes•Antigenic shift: Development of new combinations of HA and NA genes due to reassortment of viral genome subunits; can result in pandemics

### Microbiology {#cesec5}

•Orthomyxoviridae family: Derived from "ortho" (straight) and "myxo" (mucus)○Influenza A: Infects humans, birds, and pigs--18 HA and 11 NA serotypes○Influenza B: Primarily infects humans--1 HA and 1 NA serotype--2 lineages (Victoria-like and Yamagata-like)○Influenza C: Infects humans and pigs--Hemagglutinin-esterase fusion (HEF) antigen•Viral features○Enveloped, single-strand RNA viruses○Spherical (100-200 nm diameter), with helical nucleocapsid○14,000 nucleotide segmented genome (10 proteins)•Culture○Grows in several cell lines (e.g., Vero and MDCK)○Detectable by immunofluorescence after 4-8 days

### Epidemiology {#cesec6}

•Seasonal influenza A and B○Worldwide: 3-5 million hospitalizations and 250,000-500,000 deaths per year○USA: 5-20% infected, 226,000 hospitalizations, and 21,600 deaths per year•Pandemic influenza A○H3N8 Russian influenza (1889): 1 million deaths worldwide○H1N1 Spanish influenza (1918): 50 million deaths worldwide (675,000 USA)○H3N2 Asian influenza (1957): 2 million deaths worldwide (69,800 USA)○H3N2 Hong Kong influenza (1968): 1 million deaths worldwide (33,800 USA)○H1N1 Swine flu (2009): 284,000 deaths worldwide•Avian influenza (H5)○Exposure to birds in Asia, with high mortality○No person-to-person transmission

### Site {#cesec7}

•Upper and lower respiratory tract

### Presentation {#cesec8}

•Abrupt onset of fever, myalgia, headache, malaise, nonproductive cough, sore throat, and rhinitis

### Laboratory Tests {#cesec9}

•Best samples: Nasopharyngeal or nasal swab, nasal aspirate or wash (collect with 4 days of onset of illness)•Rapid antigen assays (≤ 15 minutes); 50-70% sensitive and \> 90% specific; no subtype information•Viral culture (3-10 days); essential for strain determination and surveillance•Immunofluorescence, direct (DFA) or indirect (IFA) fluorescent antibody staining (1-4 hours)•RT-PCR (1-6 hours)

### Natural History {#cesec10}

•Self-limited infection that resolves after 3-7 days (cough and malaise can last for \> 2 weeks)•Complications include viral pneumonia or secondary bacterial pneumonia, encephalopathy, transverse myelitis, myositis, myocarditis, and pericarditis

### Treatment {#cesec11}

•Primary prevention○Influenza vaccine: Recommended annually for all persons \> 6 months old--Contains HA antigen of 2 influenza A strains (i.e., H1N1 and H3N2) and 1 or 2 influenza B strains (Victoria and Yamagata)--Updated yearly to match antigenically circulating strains according to WHO predictions--Traditionally produced by egg-based methods; cell-based and recombinant vaccines approved by FDA in 2012 and 2013•Upon presentation with symptoms○Largely supportive care○M2 inhibitors: Amantadine, rimantadine--No longer used due to widespread resistance○Neuraminidase inhibitors: Oseltamivir, zanamivir○New antivirals targeting M2, neuraminidase, hemagglutinin, RNA-dependent RNA polymerase, and nucleoprotein are under development

### Prognosis {#cesec12}

•Uncommonly fatal in immunocompetent (H1N1, avian flu, influenza B in pediatric patients with myocarditis)•Highest risk at age \> 65, children, pregnant women, and those with underlying health conditions (morbid obesity, diabetes, underlying respiratory illness)

### Imaging Findings {#cesec13}

•CXR: Normal in uncomplicated disease; diffuse infiltrates, mottled densities, and consolidations in severe disease

### Macroscopic Findings {#cesec14}

•Fatal cases: Heavy, congested, edematous lungs; mucosal surfaces of trachea and bronchi hyperemic and swollen

### Microscopic Findings {#cesec15}

•Seasonal influenza A and B: Diffuse, superficial, necrotizing tracheobronchitis•Pandemic influenza A (H1N1): Inflammation of large airways and diffuse alveolar damage and hemorrhage•No viral inclusions detectable by light microscopy

### Ancillary Tests {#cesec16}

•Immunohistochemistry○Seasonal influenza A and B: Respiratory epithelial cells in distal trachea and bronchi○Pandemic influenza A (H1N1): Upper and lower airways•RT-PCR (fresh or formalin-fixed tissue) more sensitive for prolonged illness or with extensive necrosis

### Differential Diagnosis {#cesec17}

•Other infectious causes of tracheobronchitis and pneumonia○Adenovirus, respiratory syncytial virus, rhinovirus, parainfluenza viruses, coronaviruses, human metapneumoviruses, *Mycoplasma pneumoniae*, *Legionella* spp., etc.--Detection of specific pathogen by culture, direct fluorescent antibody and rapid antigen assays, serology, PCR, histochemical stains, or IHC

Other Respiratory Viruses {#cesec18}
-------------------------

### Etiology/Pathogenesis {#cesec19}

•Viral infections transmitted person to person via respiratory droplets•Human parainfluenza viruses (HPIVs)○Hemagglutinin-neuroaminidase-mediated attachment and cell uptake○Incubation period: 1-7 days•Rhinovirus optimally replicates between 33-35 °C (intranasal temperature)○Virus binds ICAM-1/CD54 receptors on respiratory epithelial cells○Incubation period 2-3 days

### Microbiology {#cesec20}

•Human parainfluenza viruses○Paramyxoviridae family: Derived from "para" (beyond) and "myxo" (mucus)○Viral features--Enveloped, single-strand RNA viruses--150-250 nm with helical capsid--15,000 nucleotide genome (6 proteins)--5 types (HPIV-1, HPIV-2, HPIV-3, HPIV-4a, HPIV-4b)○Culture--Grows in primary monkey kidney (PMK) and LLC-MK2 cells--Detection by hemadsorption with guinea pig erythrocytes within 3-10 days•Rhinoviruses: Derived from "rhino" (nose)○Picornaviridae family: Derived from "pico" (small) and "RNA"○Viral features--Nonenveloped, single-strand RNA viruses--Spherical, 30 nm with icosahedral capsid--7,200-8,500 nucleotide genomes (1 ORF)--3 species (A, B, C); \> 100 different serotypes○Culture--Grows in human fetal embryonic lung fibroblast cell lines, HeLa cells, and human embryonic kidney cell lines--Detection of cytopathic effects after 2-6 days at 33-35 °C

### Epidemiology {#cesec21}

•Human parainfluenza viruses○Common in infants/children (antibodies by age 5)○41,000 hospital admissions per year in USA (2nd highest after RSV); HPIV-1 and HPIV-2 peak in fall; HPIV-3 peak in spring/summer•Rhinoviruses○30-50% of common cold (∼ 20-33 million cases per year in USA); most common in fall and spring

### Site {#cesec22}

•Upper and lower respiratory tract

### Presentation {#cesec23}

•Human parainfluenza viruses: Fever, rhinorrhea, cough, croup/laryngotracheobronchitis (HPIV-1 and HPIV-2); bronchitis, bronchiolitis, pneumonia (HPIV-3)•Rhinoviruses: Sneezing, coughing, rhinorrhea, pharyngitis, nasal congestion, watery eyes, mild headache, mild body aches

### Laboratory Tests {#cesec24}

•Typically unnecessary for diagnosis•RT-PCR, direct viral antigen tests, viral culture, serology (IgM or rise in IgG)

### Natural History {#cesec25}

•Typically self-limited, resolves within 7-10 days

### Treatment {#cesec26}

•Primary prevention○No FDA-approved vaccines available○Good hygiene with handwashing; avoidance of sick individuals•Upon presentation with symptoms○No specific antiviral treatments available○Primarily symptomatic/supportive treatment; rest and rehydration○Hospitalization for respiratory distress, stridor, or severe dehydration

### Prognosis {#cesec27}

•Mortality rare in immunocompetent

### Imaging Findings {#cesec28}

•CXR: For evaluation of croup (classic steeple sign), epiglottitis, or pneumonia

### Macroscopic Findings {#cesec29}

•Human parainfluenza viruses: Heavy, congested, hemorrhagic, and edematous lungs•Rhinoviruses: No prominent gross findings

### Microscopic Findings {#cesec30}

•Human parainfluenza viruses: From mild tracheobronchitis to interstitial pneumonitis with mononuclear cell infiltrates, diffuse alveolar damage, multinucleated giant cells with cytoplasmic inclusions•Rhinoviruses: Minimal damage to nasal epithelium, mild inflammatory infiltrate (lymphocytes and eosinophils), neutrophils abundant in nasal lavage fluids

### Ancillary Tests {#cesec31}

•Immunohistochemistry○Human parainfluenza viruses: HPIV antigens detectable in alveolar lining cells and giant cells○Rhinoviruses: Antigens detectable in nasal epithelium•Electron microscopy○Human parainfluenza viruses: 150-300 nm enveloped virions with helical nucleocapsid○Rhinoviruses: 30 nm nonenveloped virions with icosahedral nucleocapsid

### Differential Diagnosis {#cesec32}

•Other infectious causes of tracheobronchitis, pneumonia, and giant cell pneumonia○Measles, influenza, adenoviruses, coxsackie viruses, respiratory syncytial virus, human metapneumovirus, varicella-zoster virus, herpes simplex virus, henipaviruses, *Chlamydia pneumoniae*, *Mycoplasma pneumoniae*, etc.--Detection of specific pathogen by culture, direct fluorescent antibody and rapid antigen assays, serology, PCR, histochemical stains, or IHC•Allergic rhinitis○Associated with specific allergens; may be seasonal or perennial; improves with steroids and allergen avoidance

Diagnostic Checklist {#cesec33}
--------------------

### Pathologic Interpretation Pearls {#cesec34}

•Sick-contact exposure, travel, immunization, seasonality, and immunocompetency histories essential

Key Points {#cesec35}
----------

### Etiology {#cesec36}

•Viral infections transmitted by respiratory droplets

### Clinical Issues {#cesec37}

•Millions infected yearly with seasonal variations•Severity of symptoms ranges from sneezing and rhinorrhea (rhinoviruses) to pneumonia and death (pandemic influenza)•Annual vaccines recommended for influenza; antivirals can decrease symptoms•Often diagnosed clinically, treated supportively/symptomatically

### Microscopic Pathology {#cesec38}

•Range from mild mucosal inflammatory infiltrate (rhinoviruses) to diffuse alveolar damage (pandemic influenza)•RT-PCR, viral culture, serology, IHC, and rapid antibody/antigen tests useful when specific diagnosis is needed

Lungs from a fatal case of H1N1 influenza are large (3x upper limit of normal weight) and diffusely hemorrhagic.

Section from a fatal case of H1N1 influenza shows acute and organizing lung injury consistent with a diffuse alveolar damage pattern of injury with intraalveolar hemorrhage and hemosiderosis.

Section from a fatal case of H1N1 influenza exhibits a diffuse alveolar damage pattern with hyaline membrane formation and increased collagen within the alveolar walls.

Hyaline membrane formation ![](black-open-9780323376778.gif) and increased collagen within alveolar walls are typical findings of fatal pandemic influenza infection.

Cavitating abscess formation ![](black-solid-9780323376778.gif) of at least several weeks duration is present in this section of lung from a fatal case of H1N1 influenza with bronchopneumonia.

Lateral neck radiograph of a young child with croup (likely caused by parainfluenza infection) shows marked subglottic airway narrowing ![](black-open-9780323376778.gif), overdistension of the hypopharynx ![](black-solid-9780323376778.gif), and a normal-appearing epiglottis.(From DI: Pediatrics.)
